Breakthrough: The Future of mRNA

Prognosis: Misconception

Bloomberg

Health & Fitness, Science

4.1 • 838 Ratings

🗓️ 7 December 2021

⏱️ 30 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Covid-19 is just the beginning for messenger RNA vaccines. Researchers are testing shots across a range of diseases, from cancer to malaria, HIV or even multiple sclerosis. There’s no guarantee the technology will work beyond infectious diseases, but if it does, it could transform medicine.

See omnystudio.com/listener for privacy information.

Transcript

Click on a timestamp to play from that location

0:00.0	Are you looking for a new podcast about stuff related to money?
0:05.3	Well, today's your lucky day.
0:07.1	I'm Matt Levine.
0:08.2	And I'm Katie Greifeld.
0:09.5	And we are the hosts of Money Stuff, The Podcast.
0:13.0	Every Friday, we dive into the top stories about Wall Street, finance, and other stuff.
0:17.9	We have fun. We get weird, and we want you to join us. You can listen to
0:22.0	Many Stuff the Podcasts on Apple Podcasts, Spotify, or wherever you get your podcasts.
0:29.7	A black van with tinted windows is parked in front of an art-nevo building not far from
0:36.1	Munich's English Garden. It's September.
0:40.3	The COVID-19 vaccine drive is in full swing, with countries around the world debating just who
0:46.4	should get booster shots. Inside the Munich Villa's heavy door is a narrow entry foyer
0:52.3	that leads up a wooden staircase. There's a cluster of
0:56.6	people coming down. It's Germany's star scientists, Erzlum Turechi and Uwarshahin. They're the
1:03.8	husband and wife duo behind Biontek, Pfizer's partner for the COVID vaccine, and they're on
1:10.0	their way out of a meeting with the
1:11.4	company's chairman, Helmut Yagla. Erzlund and Uwur say hello politely and then head out the door.
1:18.8	Helmut is waiting upstairs to talk to me about Biontek, and it's raced to develop a messenger RNA vaccine.
1:30.3	Helmut laughs when I ask what they talked about that day. Next generation, MRNA treatments are on everyone's mind.
1:35.3	Next generation?
1:40.3	Next generation?
1:43.3	No. Of course we have to think about how we develop the company because of the situation we're in now.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Bloomberg, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Bloomberg and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.